Covovax 5,0 μg Injection
PDF Leaflet Revision Date: 16 August 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Active immunization to prevent COVID-19 in individuals 12 years and older.
Dosage (summary)
2 doses of 0.5 ml each, second dose 3 weeks after the first.
Special Populations
- Elderly (no dose adjustment required)
- Immunocompromised individuals
Pregnancy & Breastfeeding
Limited experience in pregnancy; use only if benefits outweigh risks. Unknown if excreted in breast milk.
Key Drug Interactions
- Lower antibody response when co-administered with inactivated influenza vaccines
Contraindications
- Hypersensitivity to active substance or excipients
Common side effects
- Injection site pain
- Fatigue
- Headache
- Myalgia
- Nausea
Counselling Points
- Complete vaccination course with COVOVAX
- Report any adverse reactions
- Monitor for allergic reactions
Serious warnings
- Risk of anaphylaxis; observe for 15 mins post-vaccination
- Postpone in acute febrile illness
Important Disclaimer
The Covovax 5,0 μg Injection professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
